There is an urgent need to expand access to treatment for persons with opioid use disorder
(OUD). As neurologists may frequently encounter patients with chronic pain who have …

Introduction There is a limited literature base regarding the intersection of drug and alcohol
treatment, violence, and trauma. While research substantiates that exposure to violence and …

Aim To assess the effectiveness and cost-effectiveness of buprenorphine and methadone
treatment in the US if exemptions expanding coverage for substance use disorder services …

This study by Hammerslag et al1 found that the onset of the COVID-19 pandemic was
associated with use of telemedicine to initiate Medicaid patients on buprenorphine, a …

Introduction Patients receiving buprenorphine after a non-fatal overdose have lower risk of
future nonfatal or fatal overdose, but less is known about the relationship between …

Purpose Buprenorphine is a highly effective medication for opioid use disorder (OUD) that
remains substantially underutilized by primary care professionals (PCPs). This is particularly …

In the Healing Community Study (HCS), we aimed to show that implementation of a battery
of evidencebased interventions to expand (1) access to naloxone,(2) the number of patients …

Background Telehealth-only medication for opioid use disorder (teleMOUD) treatment with
buprenorphine was first made possible in the United States during the COVID-19 Public …

Background Opioid use disorder (OUD) is a chronic condition that requires regular visits and
care continuity. Telehealth implementation has created multiple visit modalities for OUD …

Background As the US opioid-involved morbidity and mortality increase, uptake and
implementation of evidence-based interventions remain key policy responses. Respond to …